Sentiment Summary
Recent Events
Full year results for fiscal year 2026 scheduled.
Ex-dividend date for the 2025 final dividend of HKD 0.43007 per share on 2026-07-17; market analysts justify medium impact due to dividend payout; event scheduled.
Ex-dividend date for the HK$0.88 per share final dividend for the year ended December 31, 2025, is scheduled for July 9, 2026; low importance as a routine technical adjustment is scheduled.
A quarterly dividend of C$1.14 per share, a 4% increase, is scheduled with an ex-dividend date of July 7, 2026; low importance is estimated based on the typical market reaction to dividend increases, scheduled.
The ex-dividend date for the complementary dividend payment of approximately €0.43 per share is scheduled for July 6, 2026, with an estimated 1% price impact, scheduled.
Ex-dividend date of 2026-07-03 for a proposed final dividend of RMB 0.295 per share for the year ended Dec 31, 2025, with payment on 2026-08-21 following approval on 2026-06-30; the dividend is expected to have a price impact of at least 1% scheduled
Ex-dividend date for 2025 final dividend of HK$0.38 per share, scheduled.
An extraordinary general meeting is scheduled on 2026-06-25 to vote on a new executive remuneration system and a 10% H-share repurchase mandate; 1% price impact expected.
Ex-dividend date for the proposed final dividend of RMB 0.101 per share for the fiscal year 2025. Medium impact expected due to the dividend yield's effect on the share price, scheduled.
Ex-dividend date on 2026-06-18 for the 2025 final dividend of RMB 0.25 per share, with payment scheduled for July 31, 2026; 1% price impact expected.
2025 final dividend of CNY 0.6 per share, with an ex-dividend date of June 11, 2026, scheduled.
Annual General Meeting to approve matters including the final dividend for the year ended December 31, 2025. Low impact expected as AGM approvals are typically routine, scheduled.
HSBC shares fell in London trading on 2026-06-04 following reports that Hong Kong banks are increasing scrutiny on mainland Chinese clients opening accounts to stem capital flight.
Announced board approval for FX hedging up to USD 150 million; routine risk management is estimated to have a >1% price impact.
Announced an increase in the guarantee limit for subsidiaries by RMB 300 million; operational support is estimated to have a >1% price impact.
UBS analysts lowered their target price on Wanguo Gold Group to HK$17.3 from HK$17.8, citing updated cost guidance, but maintained a 'Buy' rating estimated.
Iberdrola is in the final stages of completing the sale of its Mexican assets to Cox Group on June 3, 2026, which will likely result in a significant valuation shift exceeding 10% due to strategic refocusing, expected.
Johnson & Johnson announced on June 3, 2026, that its monoclonal antibody, nipocalimab, met the primary endpoint in the Phase 2 JASMINE study for SLE; positive clinical data for a major pipeline candidate is estimated to have a 5-10% market impact, expected.
The company went ex-dividend for its final dividend of HK$0.23 per share on June 3, 2026, with payment on June 18, 2026; a 1% price impact is estimated due to the standard dividend adjustment, scheduled.
Strategic cooperation agreement for 100 new energy mixer trucks in Tianjin is expected on June 3, 2026; low importance due to limited contract scale is expected.
Company's subsidiary ordered four 175,000 cbm LNG carriers from Jiangnan Shipyard for approximately $953 million on 2026-06-02, backed by a long-term charter with Shell; market analysts justify high impact due to significant contract value; high impact estimated.
Ex-dividend date for the first interim dividend of 2026 (HKD 0.63 per share) on 2026-06-02; low impact due to stable dividend policy expected
Ex-dividend date for the final dividend of HK$0.35 per share for the year ended December 31, 2025, on June 2, 2026; low importance estimated as dividend events typically result in minor price adjustments, scheduled.
At the AGM on June 1, 2026, management announced it is negotiating a gas price hike of about 10% with the government and forecast a potential 3% decline in H1 2026 gas sales; a 5% price impact is estimated as the hike is offset by volume decline, as management forecast estimated and scheduled.
On May 31, 2026, Johnson & Johnson announced positive final results from the Phase 3 PROTEUS study of ERLEADA in prostate cancer; successful Phase 3 results for an oncology blockbuster typically drive a 5-10% price impact, expected.
At the Annual General Meeting on May 29, 2026, shareholders are set to approve resolutions including a dividend of €0.685 per share and the ratification of Pedro Azagra as CEO, which is estimated to impact the stock price by 5%, scheduled.
Ex-dividend date on 2026-05-29 for the quarterly dividend of $0.28 per share declared on 2026-04-30. Low importance as dividends typically result in a minor 1% price adjustment scheduled.